Previous 10 | Next 10 |
Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...
Thinly traded nano cap Cellectar Biosciences ( CLRB +30.7% ) is up on a robust 32x surge in volume in reaction to preliminary data from Cohort 6 in its Phase 1 study of CLR 131 in patients with relapsed/refractory multiple myeloma. More news on: Cellectar Biosciences, Inc., Healthcare ...
Appliance Recycling Centers of America (NASDAQ: ARCI ) +19% on Q1 earnings . More news on: Appliance Recycling Centers of America, Inc., PDS Biotechnology Corporation, The Container Store Group, Inc., Stocks on the move, Read more ...
Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to be safe and well tolerated and recommends study continue to Cohort 7 FLORHAM PARK, N.J., May 15, 2019 (GLOBE NEWSWIRE) -...
Gainers: Cellectar Biosciences (NASDAQ: CLRB ) +7% . More news on: Cellectar Biosciences, Inc., INSYS Therapeutics, Inc., Soliton, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Thinly traded nano cap Cellectar Biosciences ( CLRB +5.6% ) is up on more than a 4x surge in volume on the heels of Fast Track status in the U.S. for lead candidate CLR 131 for the fourth line (or greater) treatment of relapsed/refractory multiple myeloma. More news on: Cellectar Biosc...
Amber Road (NYSE: AMBR ) +26% on being acquired by E2open. More news on: Amber Road, Inc., Onconova Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Stocks on the move, Read more ...
FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Admi...
Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.76 misses by $0.26 . Cash and cash equivalents of $10.48M Press Release More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131 in relapsed/refractory multiple myeloma ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...